Although MutSβ normally helps cells by spotting and fixing certain kinds of DNA errors, in the case of HD it can actually make things worse. The MutSβ machine can mistakenly act at CAG repeats in the ...

We’re proud to announce Gravity Guignard as a 2025 HDBuzz Prize winner! A new study points to one of the reasons why past HD trials might have failed. The good news? This shows the path to safer drugs ...

UniQure has announced positive top-line results from its Phase I/II trial of AMT-130, a one-time gene therapy being tested in people with Huntington’s disease (HD). Topline data is a summary of the ...

We’re proud to announce Chloe Langridge as a 2025 HDBuzz Prize winner! A protein called SGTA shows promise as a target in HD therapeutics. Researchers find that increasing levels of SGTA in the cell ...

September was a landmark month in Huntington’s disease research: a gene therapy shows signs of slowing progression, plus new biomarkers, mechanistic insights and mental health advances. The field has ...

People who develop Huntington’s disease (HD) are born with the genetic change that causes the disease. So why does it take decades, usually around 40 to 50 years, for the symptoms of the disease to ...

Hello from Palm Springs! The HDBuzz team are here and ready to report on all of the exciting science that we are going to hear over the next 3 days from HD experts who have travelled from all over the ...

A new CRISPR-based technology, called RIDE, is a leap forward for this trail-blazing technology. With the precision of a scalpel sharp enough to rewrite the very code of life, researchers have used it ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committee (iDMC) that ...

The Huntington Study Group (HSG) is a clinical research network focused on accelerating treatments for Huntington’s disease (HD). This year, the annual conference is being held in Cincinnati, where ...